The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF 11th Spring Conference 2020

Current and Future Challenges of Innovative Oncology Drugs Development

Noordwijk aan Zee, Netherlands – 10-12 February 2020

EVENT OUTLINE 

The Cancer Drug Development Forum (CDDF) Spring conference 2020 is a unique forum that convenes every 18 months and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives and patient advocacy groups. It is the successor of the former CDDF Alpine Conference and the 11th edition takes place from 10 to 12 February 2020, in Noordwijk aan Zee (NL).

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. The programme focuses on the latest and future challenges of Innovative oncology drug development with a special emphasis on rational combination therapies, tumor agnostic drug development, cell therapy, and the revision of EMA anti-cancer guideline.

TARGET AUDIENCE

The target is a multidisciplinary audience of representatives from academia, EU and US regulatory dodies (EMA, FDA and national agencies), the pharmaceutical Industry, HTAs and patient advocates.

PROGRAMME COMMITTEE

  • Jaap Verweij (CDDF Board, UK)
  • Stefan Schwoch (Lilly, UK)
  • Irmela Radtke (Roche, CH)
  • Paul Stockman (Astrazeneca, UK)

PROGRAMME

MEETING VENUE:

Radisson Blu Palace Hotel, Noordwijk aan Zee
Pickeplein 8,
2202 CL Noordwijk,
The Netherlands

Cancer Drug Development Forum
c/o BLSI
Clos Chapelle-aux-Champs 30
1200 Brussels, Belgium

info@cddf.org
Tel: +32 2 880 62 70

Legal address
c/o Deloitte Tirol
Wirtschaftsprüfungs GmbH,
Wilhelm-Greil-Str. 15,
6020 Innsbruck, Austria